<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, June 22, 2020 (HealthDay News) — For patients with melanoma treated with immune checkpoint inhibitors (ICIs), vitamin D intake is associated with a reduced risk for ICI colitis, according to a study published online June 22 in Cancer<\/i>.<\/p>\n
Shilpa Grover, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues performed a retrospective analysis of a discovery cohort of 213 melanoma patients who received programmed cell death-1, cytotoxic T-lymphocyte-associated antigen-4, or combination ICIs between May 2011 and October 2017. Characteristics associated with pathologically confirmed ICI colitis were assessed.<\/p>\n
The researchers found that 17 percent of the patients developed ICI colitis. Thirty-one percent of the patients had vitamin D use recorded before starting ICIs. Vitamin D use conferred a significantly lower likelihood of developing ICI colitis in a multivariable analysis (odds ratio, 0.35). In a confirmatory cohort of 169 patients, of whom 49 developed ICI colitis, similar results were seen (odds ratio, 0.46). In the discovery cohort only, pretreatment neutrophil-to-lymphocyte ratio \u22655 predicted reduced odds of colitis (odds ratio, 0.34).<\/p>\n
“The specific mechanism by which vitamin D may prevent immune-related colitis should be further explored through future correlative studies, including cytokine analyses and immune profiling at baseline and at the time of colitis,” the authors write.<\/p>\n
Several authors disclosed financial ties to the biopharmaceutical and medical technology industries.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n